Research programme: ABVIRO - Agastiya Biotech
Latest Information Update: 26 Feb 2024
At a glance
- Originator Agastiya Biotech
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Dengue
Most Recent Events
- 18 Jan 2024 Preclinical trials in COVID-2019 infections in USA (unspecified route) (Agastiya Biotech pipeline, January 2024)
- 18 Jan 2024 Preclinical trials in Dengue in USA (unspecified route) (Agastiya Biotech pipeline, January 2024)